EFFICACY AND SAFETY OF RISPERIDONE IN THE LONG-TERM TREATMENT OF PATIENTS WITH SCHIZOPHRENIA

被引：105

作者：

LINDSTROM, E

ERIKSSON, B

HELLGREN, A

VONKNORRING, L

EBERHARD, G

机构：

[1] Department of Psychiatry, University Hospital, Uppsala University, Uppsala

[2] Janssen-Cilag AB, Västra Frölunda

[3] Department of Psychiatry, Lund University, Lund

来源：

CLINICAL THERAPEUTICS | 1995年 / 17卷 / 03期

关键词：

D O I：

10.1016/0149-2918(95)80105-7

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The long-term efficacy and safety of risperidone were evaluated in patients with chronic schizophrenia in an open-label study. Thirty-two patients received risperidone for 1 year and 19 of the 32 received risperidone for 2 years. The mean dose of risperidone was 9.4 mg/d in the 1-year follow-up and 8 mg/d in the 2-year follow-up. At the end of 1 and 2 years, improvements were found in total scores on the Positive and Negative Syndrome Scale (PANSS), on four PANSS factors (positive, negative, excited, and cognitive), and the Clinical Global Impression scale. Severity of extrapyramidal symptoms (based on scores on the Extrapyramidal Symptom Rating Scale) was also reduced. Clinical improvement (defined as a 20% or more reduction in total PANSS scores) was shown by 54% of the patients at end point. Social functioning (as assessed by using the modified Strauss/Carpenter scale) was significantly improved after 2 years. Number of days spent in hospitals was significantly reduced during the 2 years of treatment, and the number of days in treatment (group) homes significantly increased. It is concluded that treatment with risperidone for 1 and 2 years is associated with significant reductions in symptoms of schizophrenia, improved social functioning, and reduction in days spent in the hospital.

引用

页码：402 / 412

页数：11

共 18 条

[1]

Borison, Pathiraja, Diamond, Et al., Risperidone: Clinical safety and efficacy in schizophrenia, Psychopharmacol Bull, 28, pp. 213-218, (1992)

[2]

Chouinard, Jones, Remington, Et al., A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients, J Clin Psychopharmacol, 13, pp. 25-40, (1993)

[3]

Marder, Meibach, Risperidone in the treatment of schizophrenia, Am J Psychiatry, 151, pp. 825-835, (1994)

[4]

Diagnostic and Statistical Manual of Mental Disorders, (1987)

[5]

Kay, Fizbein, Opler, The Positive and Negative Syndrome Scale (PANSS) for schizophrenia, Schizophr Bull, 13, pp. 261-276, (1987)

[6]

Lindstrom, von Knorring, Principal component analysis of the Swedish version of the Positive and Negative Syndrome Scale for schizophrenia, Nordic Journal of Psychiatry, 47, pp. 257-263, (1999)

[7]

Lindstrom, von Knorring, Changes in single symptoms and separate factors of the schizophrenic syndrome after treatment with risperidone or haloperidol, Pharmacopsychiatry, 27, pp. 108-113, (1993)

[8]

Lindenmayer, Bernstein-Hyman, Grochowski, Five-factor model of schizophrenia

[9]

initial validation, J Nerv Ment Dis, 182, pp. 631-638, (1994)

[10]

Guy, ECDEU Assessment Manual for Psychopharmacology, (1976)

← 1 2 →